Table 5 Joint association of XPD-751, ERCC1-118, TS-3′UTR, and GSTP1-105 polymorphisms with survival and time to progression after 5-FU/oxaliplatin chemotherapy for disseminated colorectal cancer (multivariable analysis, stratified by ECOG)

From: A multivariate analysis of genomic polymorphisms: prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer

  

Survival

Progression

Factors

No. of patients

Adj. relative riska

Adj. P-valuea

Adj. relative riskb

Adj. P-valueb

XPD-751

  

0.037

  

 Lys/Lys

40

1

   

 Lys/Gln

53

1.50 (0.79, 2.87)

   

 Gln/Gln

13

3.33 (1.39, 7.99)

   

ERCC1-118

  

0.037

  

 Favourable: C/C

30

1

   

 Unfavourable

76

2.05 (1.00, 4.20)

   

TS-3′UTR

  

0.091

 

0.020

 Favourable: +6BP/+6BP

37

1

 

1

 

 Unfavourable

65

1.65 (0.91, 2.99)

 

1.76 (1.08, 2.86)

 

 Unknown

4

    

GSTP1-105

  

0.072

 

0.018

 Val/Val

10

1

 

1

 

 Ile/Val

47

2.73 (0.88, 8.45)

 

0.96 (0.42, 2.21)

 

 Ile/Ile

49

3.25 (1.04, 10.16)

 

2.00 (0.85, 4.71)

 
  1. 5-FU=5-fluorouracil; CI=confidence interval; GSTP=glutathione S-transferase; TS=thymidylate synthase; UTR=untranslated region.
  2. aBased on Cox's proportional-hazards model, stratified by ECOG, with all four genes included for survival.
  3. bBased on Cox's proportional-hazards model, stratified by ECOG, with TS-3′UTR and GSTP1-105 for time to progression.
Back to article page